Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLRNV2)

Drug Name
AMENTOFLAVONE Drug Info
Synonyms
Amentoflavone; 1617-53-4; 3',8''-Biapigenin; Didemethyl-ginkgetin; Amenthoflavone; UNII-9I1VC79L77; MLS000574827; CHEBI:2631; 9I1VC79L77; SMR000156235; Q-100192; 8-[5-(5,7-dihydroxy-4-oxo-chromen-2-yl)-2-hydroxy-phenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 8-[5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 8-(5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5281600
ChEBI ID
CHEMBL63354
CAS Number
CAS 1617-53-4
TTD Drug ID
DMLRNV2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting GABA(A) receptor gamma-2 (GABRG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Allopregnanolone DMNLHAC Depression 6A70-6A7Z approved [7]
THIOCOLCHICOSIDE DMEPWYA Muscle spasm MB47.3 Approved [8]
ZK-93423 DMFWMKZ Epileptic seizures 8A61-8A6Z Phase 3 [9]
GSK683699 DMTW79H Inflammatory bowel disease DD72 Phase 2 [8]
ELTANOLONE DM38CIV Premenstrual syndrome GA34.40 Discontinued in Phase 3 [7]
U-78875 DM2WOPX Anxiety disorder 6B00-6B0Z Discontinued in Phase 1 [10]
CGS-9896 DM39PQI N. A. N. A. Terminated [11]
CGS-17867A DMMZJY3 Alcohol dependence 6C40.2 Terminated [12]
TBPS DMFC3XP Discovery agent N.A. Investigative [13]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Obatoclax DMPF9ZM Solid tumour/cancer 2A00-2F9Z Phase 2 [15]
AZD5991 DM7QGHO Haematological malignancy 2B33.Y Phase 1 [16]
AMG 176 DM0Q7NO Acute myeloid leukaemia 2A60 Phase 1 [16]
PRT1419 DMIKE0O Melanoma 2C30 Phase 1 [17]
ABBV-467 DM87SM9 Multiple myeloma 2A83 Phase 1 [18]
MIK665 DMTUVCG Acute myeloid leukaemia 2A60 Phase 1 [19]
AMG 397 DM7CNTG Refractory hematologic malignancy 2A85.5 Phase 1 [20]
PMID27744724-Compound-18 DM73S2C N. A. N. A. Patented [21]
Indole-based analog 2 DM0NEVC N. A. N. A. Patented [21]
PMID27744724-Compound-10 DMFKS2P N. A. N. A. Patented [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA(A) receptor alpha-5 (GABRA5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flumazenil DMPCG2L Benzodiazepine overdose PC91 Approved [22]
GSK683699 DMTW79H Inflammatory bowel disease DD72 Phase 2 [23]
Basmisanil DMQ8J0U Alzheimer disease 8A20 Phase 2 [24]
RG-7816 DMD16JK Autism spectrum disorder 6A02 Phase 1 [25]
TBPS DMFC3XP Discovery agent N.A. Investigative [22]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [26]
isonipecotic acid DMO1ZHE Discovery agent N.A. Investigative [22]
[3H]Ro154513 DMMBWKL Discovery agent N.A. Investigative [27]
[3H]CGS8216 DMLP68J Inflammation 1A00-CA43.1 Investigative [22]
CI-218872 DM0RH3S Discovery agent N.A. Investigative [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Xanthine dehydrogenase/oxidase (XDH)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Allopurinol DMLPAOB Gout FA25 Approved [29]
Febuxostat DMDEXQ0 Hyperuricaemia 5C55.Y Approved [30]
Fosdenopterin DMR0TYK Molybdenum cofactor deficiency 5B5K.A Approved [31]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [32]
Oxypurinol DMURH4X Heart failure BD10-BD13 Phase 2/3 [33]
BAICALEIN DM4C7E6 Influenza virus infection 1E30-1E32 Phase 2 [3]
Topiroxostat DMA04DE Gout FA25 Phase 2 [34]
TMX-049 DME8PFQ Diabetic nephropathy GB61.Z Phase 2 [35]
LC-350189 DMHT3CB Gout FA25 Phase 1 [36]
Azaindole derivative 5 DMD2BL3 N. A. N. A. Patented [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA(A) receptor alpha-2 (GABRA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flumazenil DMPCG2L Benzodiazepine overdose PC91 Approved [38]
GSK683699 DMTW79H Inflammatory bowel disease DD72 Phase 2 [23]
PF-4480682 DMWYJHC Neuropathic pain 8E43.0 Discontinued in Phase 2 [39]
CGS-17867A DMMZJY3 Alcohol dependence 6C40.2 Terminated [12]
TBPS DMFC3XP Discovery agent N.A. Investigative [38]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [26]
isonipecotic acid DMO1ZHE Discovery agent N.A. Investigative [38]
[3H]Ro154513 DMMBWKL Discovery agent N.A. Investigative [27]
[3H]CGS8216 DMLP68J Inflammation 1A00-CA43.1 Investigative [38]
CI-218872 DM0RH3S Discovery agent N.A. Investigative [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA(A) receptor alpha-1 (GABRA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ethanol DMDRQZU Chronic pain MG30 Approved [40]
Zolpidem DMWOSKJ Insomnia 7A00-7A0Z Approved [41]
Methoxyflurane DML0RAE Anaesthesia 9A78.6 Approved [40]
Nitrazepam DMEGIQ6 Epilepsy 8A60-8A68 Approved [40]
Allopregnanolone DMNLHAC Depression 6A70-6A7Z approved [7]
Clobazam - Lundbeck DMW1OQ0 Anxiety disorder 6B00-6B0Z Approved [40]
Hexobarbital DMQ314B Anaesthesia 9A78.6 Approved [40]
THIOCOLCHICOSIDE DMEPWYA Muscle spasm MB47.3 Approved [8]
Meprobamate DMHM93Y Anxiety Approved [40]
Zaleplon DMGFWSM Insomnia 7A00-7A0Z Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA(A) receptor alpha-3 (GABRA3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flumazenil DMPCG2L Benzodiazepine overdose PC91 Approved [43]
GSK683699 DMTW79H Inflammatory bowel disease DD72 Phase 2 [23]
Adipiplon DM821BS Sleep-wake disorder 7A00-7B2Z Phase 2 [44]
NS-2710 DMMUR6V Anxiety disorder 6B00-6B0Z Phase 2 [45]
AZD6280 DMFAZLU Anxiety disorder 6B00-6B0Z Discontinued in Phase 1 [46]
TBPS DMFC3XP Discovery agent N.A. Investigative [43]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [26]
isonipecotic acid DMO1ZHE Discovery agent N.A. Investigative [43]
[3H]Ro154513 DMMBWKL Discovery agent N.A. Investigative [27]
[3H]CGS8216 DMLP68J Inflammation 1A00-CA43.1 Investigative [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Gamma-aminobutyric acid receptor (GAR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [40]
Allopregnanolone DMNLHAC Depression 6A70-6A7Z approved [47]
THIOCOLCHICOSIDE DMEPWYA Muscle spasm MB47.3 Approved [8]
Clonazepam DMTO13J Absence epilepsy Approved [48]
Piperazine DMTY9LU Ascariasis 1F62 Approved [49]
Alpidem DMN7Y9K Anxiety disorder 6B00-6B0Z Approved [50]
Moxidectin DMYGHX5 Onchocerciasis 1F6A Approved [51]
DP-VPA DMGOXPQ Bipolar disorder 6A60 Approved [52]
ANDROSTERONE DMITJAK N. A. N. A. Phase 3 [47]
ZK-93423 DMFWMKZ Epileptic seizures 8A61-8A6Z Phase 3 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting GABA(A) receptor beta-2 (GABRB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Allopregnanolone DMNLHAC Depression 6A70-6A7Z approved [7]
THIOCOLCHICOSIDE DMEPWYA Muscle spasm MB47.3 Approved [8]
Ethchlorvynol DM53IP1 Insomnia 7A00-7A0Z Approved [40]
ZK-93423 DMFWMKZ Epileptic seizures 8A61-8A6Z Phase 3 [9]
GSK683699 DMTW79H Inflammatory bowel disease DD72 Phase 2 [8]
ELTANOLONE DM38CIV Premenstrual syndrome GA34.40 Discontinued in Phase 3 [7]
U-78875 DM2WOPX Anxiety disorder 6B00-6B0Z Discontinued in Phase 1 [53]
CGS-9896 DM39PQI N. A. N. A. Terminated [11]
TBPS DMFC3XP Discovery agent N.A. Investigative [54]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By L-dopachrome tautomerase (DCT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [55]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [56]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [57]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [58]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [58]
Mitomycin DMH0ZJE Breast cancer 2C60-2C65 Approved [59]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [60]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [59]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [61]
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [62]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prostaglandin-H2 D-isomerase (PTGDS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [63]
Selenium DM25CGV N. A. N. A. Approved [64]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [65]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [66]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [67]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [68]
Mifepristone DMGZQEF Cushing disease 5A70 Approved [69]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [70]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [71]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [72]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-1 (GABRA1) TT1MPAY GBRA1_HUMAN Inhibitor [1]
GABA(A) receptor alpha-2 (GABRA2) TTBMV1G GBRA2_HUMAN Inhibitor [1]
GABA(A) receptor alpha-3 (GABRA3) TT37EDJ GBRA3_HUMAN Inhibitor [1]
GABA(A) receptor alpha-5 (GABRA5) TTNZPQ1 GBRA5_HUMAN Inhibitor [1]
GABA(A) receptor beta-2 (GABRB2) TTZA1NY GBRB2_HUMAN Inhibitor [1]
GABA(A) receptor gamma-2 (GABRG2) TT06RH5 GBRG2_HUMAN Inhibitor [1]
Gamma-aminobutyric acid receptor (GAR) TTNJYV2 NOUNIPROTAC Inhibitor [1]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) TTL53M6 MCL1_HUMAN Inhibitor [2]
Xanthine dehydrogenase/oxidase (XDH) TT7RJY8 XDH_HUMAN Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
L-dopachrome tautomerase (DCT) OTYVNTBG TYRP2_HUMAN Gene/Protein Processing [4]
Prostaglandin-H2 D-isomerase (PTGDS) OT71NN7C PTGDS_HUMAN Protein Interaction/Cellular Processes [5]
Tyrosinase OTX54MAA TYRO_HUMAN Gene/Protein Processing [4]
UDP-glucuronosyltransferase 1-6 OTGTQ2C9 UD16_HUMAN Gene/Protein Processing [6]
UDP-glucuronosyltransferase 1A1 OTH1C8OJ UD11_HUMAN Gene/Protein Processing [6]
UDP-glucuronosyltransferase 1A10 OTOTZVEY UD110_HUMAN Gene/Protein Processing [6]
UDP-glucuronosyltransferase 1A3 OTUEOER3 UD13_HUMAN Gene/Protein Processing [6]
UDP-glucuronosyltransferase 1A4 OT4PU620 UD14_HUMAN Gene/Protein Processing [6]
UDP-glucuronosyltransferase 1A7 OTY4JJ32 UD17_HUMAN Gene/Protein Processing [6]
UDP-glucuronosyltransferase 1A8 OTTMABBG UD18_HUMAN Gene/Protein Processing [6]

References

1 Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
2 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
3 Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
4 New constituent from Podocarpus macrophyllus var. macrophyllus shows anti-tyrosinase effect and regulates tyrosinase-related proteins and mRNA in human epidermal melanocytes. Chem Pharm Bull (Tokyo). 2007 May;55(5):757-61. doi: 10.1248/cpb.55.757.
5 In silico prediction of prostaglandin D2 synthase inhibitors from herbal constituents for the treatment of hair loss. J Ethnopharmacol. 2015 Dec 4;175:470-80. doi: 10.1016/j.jep.2015.10.005. Epub 2015 Oct 9.
6 Amentoflavone is a potent broad-spectrum inhibitor of human UDP-glucuronosyltransferases. Chem Biol Interact. 2018 Mar 25;284:48-55.
7 Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
8 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
9 Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
10 3-Phenyl-substituted imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas that have high affinity at the GABAA/benzodiazepin... J Med Chem. 1996 Sep 13;39(19):3820-36.
11 Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66.
12 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 414).
14 Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6.
15 Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Clinical pipeline report, company report or official report of Prelude Therapeutics.
18 Clinical pipeline report, company report or official report of AbbVie.
19 MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
20 Clinical pipeline report, company report or official report of Amgen.
21 Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
23 New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
25 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
26 The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8.
27 Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34.
28 Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64.
29 Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
30 Clinical pipeline report, company report or official report of Takeda (2009).
31 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
32 Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
33 Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
34 QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
35 Clinical pipeline report, company report or official report of Teijin Pharma.
36 Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
37 An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
38 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
39 WO patent application no. 2014,1515,17, Methods of improving microvascular integrity.
40 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
41 Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
42 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
43 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
44 Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3.
45 GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176-202.
46 AZD6280, a novel partial -aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.J Clin Psychopharmacol.2015 Feb;35(1):22-33.
47 Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
48 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
49 Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
50 Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
51 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
52 DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
53 High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracycli... J Med Chem. 1996 Nov 8;39(23):4654-66.
54 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 411).
55 Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
56 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
57 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
58 Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004 Jun 15;64(12):4218-26.
59 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
60 Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene. 2005 Aug 4;24(33):5226-34. doi: 10.1038/sj.onc.1208519.
61 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
62 Post-transcriptional regulation of melanin biosynthetic enzymes by cAMP and resveratrol in human melanocytes. J Invest Dermatol. 2007 Sep;127(9):2216-27. doi: 10.1038/sj.jid.5700840. Epub 2007 Apr 26.
63 Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
64 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
65 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
66 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
67 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
68 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
69 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
70 Comparative ligand-binding analysis of ten human lipocalins. Biochim Biophys Acta. 2006 Feb;1764(2):161-73. doi: 10.1016/j.bbapap.2005.12.006. Epub 2006 Jan 6.
71 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
72 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.